Tekmira Pharmaceuticals Corporation Stock Toronto S.E.
Equities
TKM
CA87911B2093
Pharmaceuticals
Sales 2024 * | 12.63M 9.21M | Sales 2025 * | 13.59M 9.91M | Capitalization | 667M 486M |
---|---|---|---|---|---|
Net income 2024 * | -113M -82.41M | Net income 2025 * | -130M -94.8M | EV / Sales 2024 * | 52.8 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 49.1 x |
P/E ratio 2024 * |
-6.12
x | P/E ratio 2025 * |
-5.15
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.66% |
Latest transcript on Tekmira Pharmaceuticals Corporation
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 14-06-30 | |
David Hastings
DFI | Director of Finance/CFO | 62 | 18-06-10 |
Karen Sims
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 14-11-30 | |
James Meyers
BRD | Director/Board Member | 58 | 18-10-22 |
Daniel Burgess
BRD | Director/Board Member | 62 | 17-03-22 |
1st Jan change | Capi. | |
---|---|---|
-3.93% | 86.16B | |
+2.76% | 40.17B | |
-16.48% | 31.47B | |
+57.86% | 25.24B | |
-13.58% | 15.82B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+6.89% | 8.84B | |
-2.46% | 7.93B |